Guizhi Zhang

Guizhi Zhang

Auto-generated profile, based on publicly available information

Guizhi Zhang

Department of Nuclear Medicine, Tianjin Medical University General Hospital, Tianjin, PR China

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2015 in Life Sciences
Verified
Journal Article
Closed access
ZMZhaowei Meng
Zhaowei Meng
JTJian Tan
Jian Tan
GZGuizhi Zhang
Guizhi Zhang
WTWeijun Tian
Weijun Tian
QFQiang Fu
Qiang Fu
AUArun Upadhyaya
Arun Upadhyaya


21 August 2013 in PLOS ONE
Verified
Journal Article
Open access
SJShang-Hui Jin
Shang-Hui Jin
XMXin-Mei Ma
Xin-Mei Ma
PHPing Han
Ping Han
BWBo Wang
Bo Wang
YSYan-Guo Sun
Yan-Guo Sun
BHBing-kai Hou
Bing-kai Hou

1 May 2017 in Medicine
Verified
Journal Article
Open access
PDF file
RWRenfei Wang
Renfei Wang
YZYueqian Zhang
Yueqian Zhang
JTJian Tan
Jian Tan
GZGuizhi Zhang
Guizhi Zhang
RZRuiguo Zhang
Ruiguo Zhang
YHYajing He
Yajing He
To assess the efficacy of radioiodine therapy (RIT) and investigate the prognostic factors for patients with pulmonary metastasis secondary to differentiated thyroid carcinoma (DTC) through a retrospective study. A total of 80 patients with radioactive iodine-131 (131I)-avid pulmonary metastasis from DTC treated with 131I from 2007 to 2014 at our institution entered the study. Treatment response was mainly measured by two parameters: serum thyroglobulin (Tg) levels and post-therapeutic 131I whole-body scan (WBS). Treatment variables were assessed for statistical significance using the univariate and multivariate analyses. A receiver-operating characteristic (ROC) curve was also plotted to verify the accuracy of predictors. Of these 80 patients, the overall effective rate was 72.5% (58/80), the rates for complete response (CR), partial response (PR), and no response (NR) were 20.0%, 52.5%, and 27.5%, respectively. Univariate analysis showed that gender, pulmonary nodule size, absence or presence of extrapulmonary distant metastases, age, and Tg level at diagnosis were significantly associated with 131I therapy efficacy. Binary logistic regression analysis revealed that older patients (odds ratio [OR]:1.481, 95% confidence interval [CI]: 1.457–2.091, P = .020), subjects with higher Tg levels at diagnosis (OR: 1.046, 95% CI: 1.016–1.119, P = .014), and those with extrapulmonary distant metastases (OR: 1.185, 95%CI: 1.025–1.463, P = .020) had a higher probability of poor prognosis. The optimal cutoffs for age and Tg level to predict 131I therapy efficacy for DTC with lung metastases were 46 years old and 55.50 ng/mL, respectively, based on ROC analysis. This study indicated that most DTC patients with pulmonary metastases can obtain partial or complete remission after RIT, while older patients with higher Tg levels at diagnosis and extrapulmonary distant metastases more likely show poor prognosis.

24 July 2013 in Environmental Earth Sciences
Verified
Journal Article
Closed access
PDF file
JXJianhong Xi
Jianhong Xi
MHMengchang He
Mengchang He
GZGuizhi Zhang
Guizhi Zhang

1 October 2015 in Clinical Nuclear Medicine
Verified
Journal Article
Closed access
XSXinghua Song
Xinghua Song
ZMZhaowei Meng
Zhaowei Meng
QJQiang Jia
Qiang Jia
LZLinlin Zhang
Linlin Zhang
KXKe Xu
Ke Xu
JZJianping Zhang
Jianping Zhang
Remnant thyroid ablation is crucial in the management of patients with differentiated thyroid cancer. However, the optimal dose of radioactive I for ablation is still controversial. This study aimed to compare the success rate of different activities of I for postoperative remnant ablation in randomized controlled trials (RCTs) and to determine the optimal dose. Sources were retrieved from the Cochrane Library, Medline, Embase, Scopus, and Google Scholar until March 2014. All RCTs that assessed the efficacy of different doses of I for ablation were selected. After data extraction, statistics were performed by Review Manager 5.2 software. Seventeen RCTs were considered eligible, involving 3737 patients. The overall methodological quality of the studies was good. The rate of successful remnant ablation of low versus moderate I activities (risk ratio [RR], 0.89; 95% confidence interval [CI], 0.80-1.00; P = 0.06) and moderate versus high I activities (RR, 0.94; 95% CI, 0.89-1.00; P = 0.05) showed no significant differences. However, high I activities had 11% higher successful ablation rate than low activities with an RR of 0.89 (95% CI, 0.81-0.97; P = 0.008), which was significant. We summarized all available randomized evidence to demonstrate that high dose of I was significantly better than low dose to achieve successful remnant thyroid ablation.